GPS-ProMPT: Molecular Profiling Identifies Overtreated Prostate Cancer Subgroup

/in /by

A retrospective analysis from the Oxford GPS-ProMPT study provides further evidence that genomic profiling can reveal which prostate cancers are truly aggressive and which are not, even when clinical features suggest otherwise. The study evaluated the 17-gene Genomic Prostate Score (GPS mdx) in 409 patients managed with active surveillance, radical prostatectomy, or radiotherapy with androgen […]

Read more

RIPCORD Phase 1 Trial: Interim PSMA PET–Guided Adaptive Radiotherapy in Metastatic Castration-Sensitive Prostate Cancer

/in , , /by

RIPCORD is a UT Southwestern phase 1 trial testing a simple but important idea: can PSMA PET be used during treatment to decide how much metastasis-directed radiotherapy a patient actually needs? It focuses on men with poly-metastatic castration-sensitive prostate cancer and uses interim 68Ga-PSMA-11 PET to adapt stereotactic ablative radiotherapy (SABR) rather than giving every […]

Read more

Phase 1 Trial: 177Lu-PSMA-617 Plus Darolutamide in High-Risk Localized Prostate Cancer

/in , , /by

A new trial phase 1 trial is investigating the combination of 177Lu-PSMA-617 (Pluvicto) with darolutamide in high-risk localized prostate cancer. Both agents are already established in prostate cancer care, but using them together before surgery is a novel way to intensify treatment in patients whose disease is still potentially curable. Its main idea is simple: […]

Read more

GRPR-Targeted Radioligand Therapy in Prostate Cancer: The A9-0631 and A9-0642 Trial

/in , , , , /by

A new first-in-human study is testing whether GRPR-targeted radiopharmaceuticals can extend precision oncology beyond the PSMA and SSTR frameworks. The trial combines two therapeutic agents, 177Lu-A9-0631 and 225Ac-A9-0642, with GRPR imaging using 68Ga-A9-6217 or low-dose 177Lu-A9-0631 in patients with GRPR-positive solid tumors. GRPR, or gastrin-releasing peptide receptor, is an appealing target because it is overexpressed […]

Read more

ARTO Trial Final Results: Long-Term Survival Benefit of SBRT Added to Abiraterone in Oligometastatic mCRPC

/in , , /by

The phase 2 ARTO trial findings, published on The Lancet, provides stronger evidence that metastasis-directed SBRT can improve outcomes in oligometastatic castration-resistant prostate cancer. In this randomized study, 157 patients were enrolled across 16 academic and community centers in Italy and assigned 1:1 to abiraterone plus ADT with or without SBRT to all visible metastatic […]

Read more

Bavdegalutamide Plus Abiraterone in Metastatic Prostate Cancer: Phase Ib Safety and Activity Results

/in , , /by

Bavdegalutamide (ARV-110) is an oral androgen receptor degrader designed to address resistance to androgen-receptor–targeted therapy in metastatic prostate cancer. In this phase 1b study, it was combined with abiraterone in patients whose disease was progressing on abiraterone, with the goal of testing safety, pharmacokinetics, and early signs of antitumor activity. The trial enrolled 45 patients, […]

Read more

Intensified Radiotherapy for Prostate Cancer Bone Metastases

/in /by

A regional retrospective study covering 2011 to 2025 suggests that a more intensive radiotherapy strategy may improve survival in selected patients with prostate cancer and bone metastases. The analysis included 246 consecutive men who received 347 radiotherapy courses and asked whether treating bone lesions more aggressively, together with prostate-directed radiotherapy, could translate into longer overall […]

Read more

Another Phase 1/2 Trial With SX-682, Combined With Docetaxel This Time

/in , , , /by

SX-682 is moving into a new clinical context. After an ongoing trial in prostate cancer with androgen receptor pathway inhibitors such as apalutamide and enzalutamide, the CXCR1/2 inhibitor is now being studied with docetaxel in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer. That matters because docetaxel is not […]

Read more